13F Holdings
中文EN

LKFT Lakefront Biotherapeutics NV IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1421876 · Reporting currency EUR

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY303.5%
TTM net income YoY333.1%
TTM EPS YoY334.8%
Revenue 3-yr CAGR66.4%
Net income 3-yr CAGR—

Margins

Gross margin97.3%
Operating margin26.5%
Net margin28.9%
FCF margin-24.4%
EBITDA margin—

Returns

ROE10.5%
ROA8.5%
ROIC (approx.)9.9%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets5.0%
Debt / equity0.00x
Current ratio20.15x
Interest coverage285.34x

Cash quality & payout

Operating cash flow / net income-0.80x
Accruals ratio15.3%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue1.11B275.65M239.72M241.25M234.38M
Cost of revenue29.74M34.86M—12.08M1.63M
Gross profit1.08B240.79M—229.17M232.75M
R&D expense459.42M335.46M241.29M269.80M320.50M
SG&A expense147.33M117.25M128.29M135.16M127.74M
Operating income295.04M-188.34M-88.26M-131.06M-171.57M
Interest expense1.03M911,0001.77M6.88M11.59M
Pretax income300.87M-3.08M5.62M-70.85M-119.40M
Income tax-18.62M-1.80M9.61M572,0001.39M
Net income320.88M74.08M211.70M-217.99M-103.23M
EPS (basic)4.871.123.21-3.32-1.58
EPS (diluted)4.871.123.21-3.32-1.58
Weighted avg. shares (diluted)65.90M65.90M65.88M65.70M—
Balance sheet
Cash & equivalents87.87M64.24M166.80M508.12M2.23B
Short-term investments2.91B3.05B3.52B3.59B2.47B
Receivables20.71M47.48M28.45M40.43M111.34M
Inventory22.49M51.19M73.98M52.92M20.57M
Current assets3.08B3.34B3.86B4.24B4.86B
PP&E, netmay include right-of-use assets (IFRS)71.95M105.40M111.22M126.73M105.72M
Goodwill—70.01M69.56M69.81M—
Intangibles848,000164.86M127.91M146.35M60.10M
Total assets3.41B4.14B4.36B4.73B5.19B
Current liabilities152.86M335.08M428.22M522.54M566.47M
Total liabilities170.65M1.24B1.56B2.21B2.55B
Shareholders' equity3.24B2.90B2.80B2.53B2.64B
Cash flow statement
Operating cash flow-257.46M-320.03M-405.97M-500.54M-503.83M
Capital expenditure13.70M16.72M18.71M27.39M54.20M
Free cash flow-271.16M-336.75M-424.68M-527.93M-558.03M
Investing cash flow288.81M220.60M71.19M-1.25B541.24M
Financing cash flow-3.27M-4.92M-5.00M-1.49M-3.88M
Stock-based compensation24.00M19.89M56.72M88.51M70.73M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.